Moleculin Biotech, Inc.
MBRX · XNASCIK 1659617fmd_1KP3QK5T6E8B3EEVN5NHRS2S4RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Research and development | 1 | 5 | 10 | 11 | 13 | 14 | 19 | 19 | 18 | 16 |
| Total operating expenses | 4 | 9 | 15 | 18 | 20 | 23 | 31 | 30 | 27 | 25 |
| Operating income | (4) | (9) | (15) | (18) | (20) | (23) | (31) | (30) | (27) | (25) |
| Interest expense | 0 | 0 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | – | 0 | (0) | 0 | 0 | 0 | 0 | 0 | 0 | (0) |
| Income before taxes | – | – | – | (13) | (17) | – | – | – | (26) | (34) |
| Income tax expense | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (13) | (17) | – | – | – | (26) | (34) |
| Net income | (4) | (10) | (12) | (13) | (17) | (16) | (29) | (30) | (26) | (34) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (26) | (34) |